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Introduction: In the last decades, life expectancy of persons with Down syndrome (DS)
has dramatically increased and it is estimated that they will be living as long as the general
population within a generation. Despite being included among the progeroid syndromes,
because of the presence of features typically observed in older adults, DS is still regarded
as a disease of pediatric interest. Because limited knowledge is available on the clinical char-
acteristics of adults with DS, this study aimed to assess clinical and non-clinical features
of this population and to describe similarities to the geriatric population.
Methods: In this study, we described 60 adults with DS evaluated at the Day Hospital of
the Geriatric Department of the Policlinico A. Gemelli, Università Cattolica del Sacro Cuore
in Rome. Individuals were assessed through a standardized protocol.
Results: The mean age of study participants was 38 years (range, 18–58 years) and 42
(70.0%) were women. Geriatric conditions were highly prevalent: severe cognitive impair-
ment was diagnosed in 39 (65.0%) participants, behavioral symptoms were present in 25
(41.7%), and functional impairment in 23 (38.3%). Six (10.0%) participants lived in institu-
tions and 11 (18.3%) were diagnosed as obese. The mean number of drugs used was 2.4;
use of psychotropic drugs was highly prevalent.The most common chronic diseases were
thyroid problems (44, 73.3%), followed by mood disorders (19, 31.7%), osteoporosis (18,
30.0%), and cardiac problems (10, 16.7%). Geriatric conditions and chronic diseases were
more prevalent among participants aged ≥40 years.
Conclusion: Several similarities between older adults and adults with DS were observed.
Comorbidities, geriatric conditions, cognitive and functional deficits, and social problems
are highly prevalent in both populations, contributing to the high complexity of these
patients’ assessment and treatment.
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INTRODUCTION
People with Down syndrome (DS) are known to have shortened
life spans. In the last century, however, their life expectancy has
dramatically increased, from 9 years in 1929 (1) to 60 years in 2002
(2–4). It was estimated that persons with DS will be living as long
as the general population within a generation (5).
This improvement in survival has been attributed to three
major changes in the approach to persons with DS. First, their vul-
nerability to respiratory infections, due to an impaired immune
system, has been addressed by the widespread availability of antibi-
otic therapies since 1950s. Beginning in the 1970s, the prevention
of respiratory infections was improved further by the trend toward
deinstitutionalization; DS patients were moved into home care or
sheltered housing. Congenital heart problems, which affect almost
half of the persons with DS and are responsible for the high rate
of early mortality, have been treated increasingly with early heart
surgery since 1980s.
Given this demographic change, DS can no longer be consid-
ered a “pediatric” disease; rather it is a condition that affects the
whole life span. So far, researchers have studied comprehensively
pediatric conditions related to DS; however, it is now time to focus
investigations on the characteristics and treatment of adults with
this condition.
Adults with DS are known to age prematurely and to present
with chronic conditions resembling those of their elders. A model
of biological age vs. chronological age showed that people with
DS age both earlier and faster than healthy controls (6). Indeed,
DS is considered a segmental progeroid syndrome (7, 8), in
which the premature aging process affects selected organ systems,
including the central nervous, immune, respiratory, gastroin-
testinal, musculoskeletal, urinary, endocrine, vision and hearing
systems (9). During their life span, persons with DS experi-
ence somatic degenerative changes such as hair graying and loss,
increased tissue lipofuscin, variations in the distribution of adi-
pose tissue, amyloidosis, increased autoimmunity, and cataracts;
these changes occur earlier than in persons with other types
of intellectual disabilities (10). Histological changes in the cen-
tral nervous system (CNS) are almost identical to those seen
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in Alzheimer’s disease (AD) and appear prematurely in persons
with DS.
Premature aging in DS produces patterns of comorbidities sim-
ilar to those found in the elderly patient. Common conditions
encountered in adults with DS include: AD, epilepsy, mood and
behavioral disorders, visual and hearing impairment, osteoporo-
sis, osteoarthritis, and autoimmune diseases, such as thyroiditis
and celiac disease. Trajectories of disease, which compare DS with
general populations, now show increased prevalence and prema-
ture onset of visual and hearing impairment, epilepsy, thyroid
disorders, and dementia in the DS population (11).
Despite the fact that clinical characteristics of adults with DS
seem to resemble those of the geriatric population, to date, lim-
ited research has systematically assessed the chronic diseases and
geriatric conditions affecting this population. The present study
aims to describe the clinical and non-clinical characteristics of
adults with DS evaluated at the Day Hospital (DH) of the Geriatric
Department of the Policlinico A. Gemelli, Università Cattolica del
Sacro Cuore in Rome, focusing on geriatric conditions, including
functional and cognitive deficits, and comorbidities.
MATERIALS AND METHODS
PARTICIPANTS
Participants were adults with DS, aged 18 years or older, assessed at
the DH of the Geriatric Department of the Policlinico A. Gemelli,
Università Cattolica del Sacro Cuore in Rome. No specific inclu-
sion criterion was required to be admitted to the DH except for
age 18 years or older. Participants were referred to the DH by DS
associations and family physicians.
Informed consent was obtained from all participants. The sur-
rogate legal representative was asked to get the information and
sign the consent form in those cases where individuals were cogni-
tively impaired or unable to make the decision for themselves. The
study was approved by the Ethical Committee of the Università
Cattolica del Sacro Cuore.
All adults with DS received a comprehensive clinical assess-
ment, following a standardized protocol that included physical
exam, EKG, blood sampling, formal neuropsychological eval-
uation, echocardiography, DEXA scan, nutritional assessment
and in selected cases hearing evaluation, pulmonary evaluation
for obstructive sleep apnea syndrome, and gastroenterological
evaluation for celiac disease.
Cognitive status was assessed using the Wechsler Adult Intelli-
gence Scale [WAIS-IV (12)]. This scale was shown to be a valid and
reliable instrument to assess cognitive status in persons with intel-
lectual disabilities; a score <45 defined severe cognitive impair-
ment. Functional status was evaluated using Basic Activities of
Daily Living (ADL) (13). This scale was largely used to assess
functional status in persons with intellectual disabilities (14–16).
Functional impairment was defined as dependency in 1 or more
ADLs. Nutritional status was assessed using body mass index;
malnutrition defined as BMI <18.5 kg/m2 and obesity as BMI
≥30 kg/m2. Behavioral symptoms were considered to be present if
the participant was using an antipsychotic drug or exhibited one
or more symptoms in the last 3 days prior to the assessment: wan-
dering, verbal abuse (i.e., threatening, screaming at or cursing oth-
ers); physical abuse (i.e., hitting, shoving, scratching, or sexually
abusing others); socially inappropriate or disruptive behavior (i.e.,
include making disruptive sounds or noises, screaming out, smear-
ing or throwing food or feces, hoarding, and rummaging through
others’ belongings); resisting care (i.e., include verbal or physical
resistance to taking medications, taking injections, completing a
variety of ADL, or eating).
Chronic conditions included: epilepsy, thyroid problems,osteo-
porosis, mood disorders, and cardiac problems (including history
of congenital heart defects, history of heart surgery, heart fail-
ure, and atrial fibrillation). Chronic conditions were assessed by
gathering information from the participant, the general practi-
tioner,and by careful review of charts. Psychotropic drugs included
antipsychotics, benzodiazepines, antiepileptics, and antidepres-
sants.
Assessment was performed by trained clinical staff. Data from
60 adults with DS that completed the clinical assessment (see
below) are presented in this manuscript.
DATA ANALYSIS
For comparisons, the study population was divided in these two
age groups: ≥40 and <40 years of age. These groups were based
on the increased prevalence of chronic diseases, including AD,
after 40 years of age (17–19). To compare characteristics of partic-
ipants based on age groups, we used ANOVA analyses for normally
distributed variables, non-parametric Mann–Whitney U -test for
skewed variables, and Fisher’s exact test for dichotomous variables.
Data were analyzed using SPSS (version 18.0).
RESULTS
The mean age of the 60 adults with DS was 38 years (range 18–
58 years) and 42 (70%) were women. In the<40 years group were
33 participants (mean age, 29.5± 6.4; 57.6% females), whereas
there were 27 in the≥40 years group (mean age, 46.0± 4.6; 85.2%
females). The main characteristics of study population according
to age group are presented in Table 1.
Geriatric conditions were common in both groups. Severe cog-
nitive impairment was diagnosed in 26 (78.8%) participants in
the <40-year age group and in 13 (48.1%) of the ≥40 group.
Behavioral symptoms were present in 11 (33.3%) and 14 (51.9%)
of the <40 and ≥40 groups, respectively. Eight (24.2%) persons
were functionally impaired in the <40 group, in contrast with
15 (55.6%) in the≥40 group. Six (22.2%) participants in the≥40
group lived in institutions. Malnutrition was uncommon, whereas
obesity was more prevalent, affecting 4 (12.1%) and 7 (25.9%)
individuals in the <40 and ≥40 groups, respectively. The mean
number of drugs used was 2.0 in the younger group and 3.0 in
the older group, with a high prevalence of psychotropic drug use,
particularly in those ≥40 years of age (Figure 1).
The most common chronic diseases were thyroid problems,
followed by mood disorders and osteoporosis. Figure 2 shows
that osteoporosis was a common condition in both males and
females. Epilepsy was more prevalent in the ≥40 group, affecting
five (18.5%) persons compared with 1 (3%) of the <40 group.
Finally, cardiac problems were diagnosed in four (12.1%) persons
of the <40 group and in six (22.2%) of the ≥40 group. Interest-
ingly, none of the participants was diagnosed with ischemic heart
disease or stroke.
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Table 1 | Characteristics of the study population according to age
group.
Age
<40 years;
n=33
(55%)
Age
≥40 years,
n=27
(45%)
p-value
Demographic characteristics
Age 29.5±6.4 46.0±4.6 <0.001
Female gender 19 (57.6%) 23 (85.2%) 0.020
Geriatric conditions
Severe cognitive impairment 26 (78.8%) 13 (48.1%) 0.001
Behavioral symptoms 11 (33.3%) 14 (51.9%) 0.191
Functional impairment 8 (24.2%) 15 (55.6%) 0.017
Number of impaired ADL 0.5±1.1 1.5±1.5 0.005
Institutionalization 0 (0.0%) 6 (22.2%) 0.006
Number of drugs used 2.0±1.2 3.0±1.4 0.016
Use of any psychotropic drugs 6 (18.2%) 17 (63.0%) 0.001
Nutritional problems
Malnutrition (BMI <18.5 kg/m2) 1 (3.0%) 0 (0.0%) 1.000
Obesity (BMI ≥30.0 kg/m2) 4 (12.1%) 7 (25.9%) 0.197
Chronic diseases
Epilepsy 1 (3.0%) 5 (18.5%) 0.081
Thyroid problems 24 (72.7%) 20 (74.1%) 1.000
Osteoporosis 7 (21.2%) 11 (40.7%) 0.156
Mood disorders 8 (24.2%) 11 (40.7%) 0.265
Cardiac problems 4 (12.1%) 6 (22.2%) 0.322
Values are reported as mean±SD or frequency (%).
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FIGURE 1 | Prevalence of use of psychotropic drugs by age groups.
DISCUSSION
Down syndrome has been historically considered as a pediatric
condition. This was due to the very short life span of this pop-
ulation in the past, with only a few people surpassing 18 years
of age. As the life expectancy of this population increased, new
health issues emerged, making the care of this population particu-
larly challenging. Adults with DS are characterized by the presence
FemalesMales
P
re
v
a
le
n
c
e
(%
)
100%
80%
60%
40%
20%
0%
OsteoporosisOsteopeniaNormal
FIGURE 2 | Prevalence of osteopenia and osteoporosis by gender.
of several concomitant, overlapping clinical conditions; they usu-
ally receive multiple medications and treatments, in particular,
psychotropic medications, and sometimes face inadequate social
and family support. The complexity of this population is further
complicated by the presence of functional and cognitive impair-
ments, which increase the risk of developing specific syndromes,
including behavioral and nutritional problems. Prevalence of these
conditions increases after 40 years of age. This complexity of care
required by this patient population surpasses the traditional prac-
tice of medicine and it resembles care that is usually required by
older adults (11).
Indeed, there is growing debate about which type of providers
delivers the highest quality of care for adults with DS and a wide
variety of comorbidities (11, 20). Families and associations often
feel abandoned by institutions and health services as their rel-
atives and assisted persons surpass the age of 18 years. Given the
high prevalence of comorbidities, functional and cognitive impair-
ment, polypharmacy, and geriatric conditions, geriatric care might
be considered as a possible option for the care of adults with DS.
Geriatric care has been shown to have a relevant impact on
the assessment and treatment of overlapping conditions and
this effect is independent of patient age. Comprehensive Geri-
atric Assessment (CGA) can evaluate the diverse problems facing
the adult with DS, including his/her comorbidities, syndromes,
socio-economic problems, and functional and cognitive deficits,
which are not usually addressed by traditional medical assess-
ments. CGA provides a more individualized and comprehensive
care plan for a single patient. CGA and geriatric care in adults
with DS have the potential to increase diagnostic accuracy; opti-
mize medical treatment; improve prognosis; restore, maintain, and
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maximize functional autonomy; compensate for the loss of auton-
omy with appropriate support services; improve quality of life; and
ultimately reduce costs of care.
A model of care already adopted for complex older adults could
thus be tested and implemented in adults with DS. Such a model
could be based on a close interaction between general practitioners
and a team of geriatricians trained in multidimensional assess-
ment of adults with DS. While the general practitioner would
ensure the continuity of care, the geriatric team would simplify
the transition process from pediatric to adult care coordinating
the multidisciplinary care for complex and chronic conditions.
Indeed, the care of adults with DS is still an open research field
and researchers need to address several issues:
1. Clear data on the prevalence of chronic diseases and geriatric
conditions (i.e., falls and fractures, behavioral symptoms, nutri-
tional problems, etc.) are lacking, and large epidemiological
studies are needed to identify risk factors in this population.
Indeed, as observed for older adults, “traditional” risk factors,
derived from a general population, might either be weakly
associated with negative events or positively affect clinical
outcomes.
2. Protocols for screening for chronic diseases and conditions are
lacking. Standardized protocols are available for screening chil-
dren with DS for most common diseases; however, a general
consensus on which chronic diseases and conditions should be
screened, available, and valid screening tools, appropriate age
to start screening and frequency of screening are not available
for adults with DS.
3. Little is known about treatment of diseases and conditions
observed in adults with DS. For example, clinical trials showed
that treatment with donepezil (21) or memantine (22) does not
improve cognition in AD-like dementia (23–26). Osteoporosis
is an extremely prevalent disease in adults with DS (27–32), but
no data are available on its effective treatment. Indeed, low bone
formation and decreased bone turnover, rather than increased
bone resorption, could be the primary cause of osteoporosis
in adults with DS (27). Therefore, it might be hypothesized
that agents that inhibit bone resorption (i.e., bisphosphonates
and denosumab) might not be the best choice in this popu-
lation. This lack of data on effective treatment for common
diseases from trials in the DS population, a further similarity
to the geriatric population, will require physicians to generalize
from findings obtained from a general population. However,
the extrapolation of evidence from studies performed in a gen-
eral population to subgroups of patients (i.e., complex older
adults or adults with DS), is not straightforward and should
consider multiple issues, including patients’ risk factors and
competing diseases and conditions.
An important limitation of this study relates to generalizability
of the results. Our findings, which are based on a sample of adults
with DS referred for assessment to a single center, which cannot
be representative of the whole population of adults with DS.
In conclusion, the present study suggests several similarities
between complex older adults and adults with DS. Comorbidi-
ties, geriatric conditions, cognitive and functional deficits, and
social problems are highly prevalent in both populations. Due
to these similarities, geriatric care based on CGA may pro-
vide the most appropriate care to persons with DS as they
grow to adulthood. Further research is needed to test such
model of care and to better understand the epidemiology and
treatment of diseases and conditions associated with DS in
adulthood.
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